checkAd

     131  0 Kommentare Cue Biopharma Begins Dosing Cohort 5 in an Ongoing Phase 1 Monotherapy Trial of CUE-101 in HPV+ Recurrent/Metastatic Head and Neck Cancer - Seite 3

    Investor Contact
    Ashley R. Robinson
    LifeSci Advisors
    arr@lifesciadvisors.com

    Media Contact
     Alison Chen
    LifeSci Communications
    achen@lifescicomms.com

    Lesen Sie auch

     



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Cue Biopharma Begins Dosing Cohort 5 in an Ongoing Phase 1 Monotherapy Trial of CUE-101 in HPV+ Recurrent/Metastatic Head and Neck Cancer - Seite 3 CUE-101 advances to cohort 5 following Safety Review Committee assessment of expanded cohort 4Cohort 5 is fully enrolled, with first patient having been dosed on July 20 Additional patients to be enrolled in cohort 4 to further characterize …